Stockscreener 앱 받기
2.78
2.21%
0.06
시간 외 거래:
2.78
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
StockNews.com Upgrades Galectin Therapeutics (NASDAQ:GALT) to "Hold" - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com - Defense World
Non-alcoholic Steatohepatitis Treatment Market Projected to Show Strong Growth - openPR
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times
Galectin Therapeutics Advances NAVIGATE Trial for MASH Cirrhosis Treatment, December Readout on Track | GALT Stock News - StockTitan
HC Wainwright Analysts Decrease Earnings Estimates for GALT - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Earns Buy Rating from HC Wainwright - MarketBeat
Galectin Therapeutics Reports Increased Q3 Losses - TipRanks
Galectin Therapeutics Inc (GALT) Quarterly 10-Q Report - Quartzy
Galectin Therapeutics Advances Galectin-Based Therapeutics Pipeline - TipRanks
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - The Manila Times
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21 - The Manila Times
Galectin Q3 Loss Narrows to $11.2M; Key NAVIGATE Trial Results Due December | GALT Stock News - StockTitan
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight - The Malaysian Reserve
Galectin Therapeutics (NASDAQ: GALT): Disrupting Merck’s Cancer Dominance - Insider Financial
Individual investors who hold 54% of Galectin Therapeutics Inc. (NASDAQ:GALT) gained 12%, insiders profited as well - Simply Wall St
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
Non-Alcoholic Steatohepatitis Market to Show Remarkable - openPR
Psoriasis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Recent Developments | Astrazeneca, Bayer, Sanofi, Pfizer, Merck, Novartis - Barchart
Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, - openPR
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Galectin therapeutics director Eldred Kary buys $1,300 in stock By Investing.com - Investing.com South Africa
Galectin therapeutics director Eldred Kary buys $1,300 in stock - Investing.com
Galectin therapeutics director Freeman buys $27,000 in stock By Investing.com - Investing.com Canada
Galectin therapeutics director Freeman buys $27,000 in stock - Investing.com
Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $13,500.00 in Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at StockNews.com - Defense World
Application Monitoring Suites Market Size and Industry Overview - News in Assen
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: - openPR
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Nonalcoholic Steatohepatitis Treatment Market Size, Innovations Driving Market Evolution (2024-2034) - IndiaPolitics.com
Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World
Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World
AXT, Inc. (NASDAQ:AXTI) Stock Holdings Trimmed by Marshall Wace LLP - Defense World
The Manufacturers Life Insurance Company Has $951,000 Stock Holdings in Huntsman Co. (NYSE:HUN) - Defense World
Marshall Wace LLP Buys New Holdings in Hanesbrands Inc. (NYSE:HBI) - Defense World
Research Analysts’ Updated EPS Estimates for October 6th (APVO, CNP, FDX, FLNT, FRD, GALT, HOPE, KBR, LSXMK, NVGS) - Defense World
Galectin Therapeutics (NASDAQ:GALT) Rating Increased to Hold at StockNews.com - Defense World
Galectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.com - MarketBeat
Global Non-Alcoholic Steatohepatitis Treatment Market Overview And Statistics For 2024-2033 - EIN News
Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight - The Malaysian Reserve
Rhumbline Advisers Purchases New Holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference - The Manila Times
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - The Manila Times
Galectin Therapeutics (FRA:PHPN) Interest Expense : €-3.71 Mil (TTM As of Jun. 2024) - GuruFocus.com
Galectin Therapeutics (FRA:PHPN) Change In Prepaid Assets : €-0.16 Mil (TTM As of Jun. 2024) - GuruFocus.com
StockNews.com Lowers Galectin Therapeutics (NASDAQ:GALT) to Sell - MarketBeat
Bank of New York Mellon Corp Purchases Shares of 64,423 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin 3 Market: Report Trends and Future Forecast Until (2024-2034) - Apiculture Market: Report ...
Global Non Alcoholic Steatohepatitis Market to Hit $ 108428.91 Million by 2032, Growing at 60.1% CAGR - 대구포스트
Galectin Therapeutics (FRA:PHPN) Enterprise Value : €217.44 Mil (As of Sep. 21, 2024) - GuruFocus.com
Galectin Therapeutics (NASDAQ:GALT) Upgraded to “Hold” at StockNews.com - Defense World
Cirrhosis Pipeline Insights, Clinical Trials, Treatment Drugs, and Companies 2024 - openPR
1.89%
2.08%
자본화:
|
볼륨(24시간):